High Growth Tech Stocks in Australia Featuring These 3 Promising Companies

In This Article:

The Australian market has climbed 1.4% in the last 7 days, led by a gain of 2.3%, and over the past year, it has risen by 15%, with earnings expected to grow by 12% per annum over the next few years. In this favorable environment, identifying high-growth tech stocks that align with these robust market conditions can offer promising investment opportunities.

Top 10 High Growth Tech Companies In Australia

Name

Revenue Growth

Earnings Growth

Growth Rating

Clinuvel Pharmaceuticals

22.32%

27.42%

★★★★★★

Pureprofile

14.94%

80.73%

★★★★★☆

Adherium

103.59%

120.00%

★★★★★★

ImExHS

20.47%

111.20%

★★★★★★

DUG Technology

10.79%

31.83%

★★★★★☆

AVA Risk Group

32.56%

118.83%

★★★★★★

Careteq

37.17%

126.21%

★★★★★☆

Pointerra

56.62%

126.45%

★★★★★★

Wrkr

36.31%

100.29%

★★★★★★

Adveritas

57.98%

144.21%

★★★★★★

Click here to see the full list of 64 stocks from our ASX High Growth Tech and AI Stocks screener.

Let's dive into some prime choices out of from the screener.

Pro Medicus

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Pro Medicus Limited is a healthcare informatics company that develops and supplies healthcare imaging software and radiology information system (RIS) software and services to hospitals, imaging centers, and healthcare groups in Australia, North America, and Europe, with a market cap of A$18.30 billion.

Operations: Pro Medicus generates revenue primarily from producing integrated software applications for the healthcare industry, amounting to A$161.50 million. The company serves hospitals, imaging centers, and healthcare groups across Australia, North America, and Europe.

Pro Medicus, a standout in the Australian tech landscape, recently showcased robust financial growth with its yearly revenue jumping to AUD 166.33 million from AUD 127.33 million, an increase reflecting a strong 16.7% growth rate. This performance is complemented by an impressive net income rise to AUD 82.79 million, up from AUD 60.65 million last year, marking an earnings surge of approximately 36.5% over the past year—significantly outpacing the industry average of 13.9%. Notably, R&D investments remain pivotal for Pro Medicus as they continue to innovate within healthcare technology—a sector demanding constant advancement. Looking ahead, Pro Medicus appears well-positioned for sustained growth with earnings expected to climb by another 18.7% annually, outstripping broader market projections of a 12.3% increase in Australia's tech sector revenues and profits are forecasted at this higher trajectory due in part to their strategic focus on high-quality non-cash earnings and efficient capital management evidenced by their recent dividend hike of over one-third to a fully franked annual rate of $0.40 per share.